<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938154</url>
  </required_header>
  <id_info>
    <org_study_id>H21-00728</org_study_id>
    <nct_id>NCT04938154</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of Deep Brain Stimulation for Spasmodic Dysphonia</brief_title>
  <official_title>A Phase 2 Trial of Deep Brain Stimulation for Spasmodic Dysphonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spasmodic Dysphonia (SD) is a focal, action-specific movement disorder with prominent effects&#xD;
      on speech (1, 2). Patients with SD lose their ability to speak normally due to involuntary&#xD;
      contractions of their laryngeal muscles. As a result, SD tremendously affects an individual's&#xD;
      quality of life by limiting their ability to communicate effectively.&#xD;
&#xD;
      The current standard of care for SD involves botulinum toxin (BTX) injections into the&#xD;
      laryngeal muscles. BTX causes a weakness in the injected muscles thereby lessening the spasms&#xD;
      (3). The primary neurological problem is not changed but weakening the muscles temporarily&#xD;
      diminishes the symptoms. However, BTX therapy is associated with several limitations (3, 4).&#xD;
      First, the clinical effect produced by BTX is temporary and repeated injections are required&#xD;
      approximately every 3 months. Second, there is a delay in the onset of benefits provided by&#xD;
      BTX injections; this delay results in a sinusoidal symptom curve where SD is optimally&#xD;
      controlled for only a portion of each treatment cycle and patients' spasms return prior to&#xD;
      the next injection cycle. Furthermore, the injections can be very painful and some patients&#xD;
      develop antibodies to BTX (3, 4). Oral medications used in dystonia, such as&#xD;
      anticholinergics, benzodiazepines, and baclofen, provide minimal relief and have numerous&#xD;
      side effects at the doses required to influence a patient's voice. Thus, on basis of these&#xD;
      limitations, we set out to explore new and innovative strategies to treat SD and provide&#xD;
      patients with long-term benefit.&#xD;
&#xD;
      Deep Brain Stimulation (DBS) is a neurosurgical procedure that involves the implantation of&#xD;
      electrodes to deliver electrical stimuli to specific brain regions. It is the gold-standard&#xD;
      surgical treatment for other movement disorders such as Parkinson's disease and generalized&#xD;
      dystonia. During a DBS procedure, an electrode is inserted very precisely into the brain and&#xD;
      is linked to a pacemaker implanted under the skin of the chest or abdominal wall. When the&#xD;
      pacemaker is switched on, a very small electric current passes into the brain, blocking the&#xD;
      damaging signals that cause the condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Voice-Related Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>The primary outcome will assess patient quality of life using the Voice-Related Quality of Life questionnaire.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Spasmodic Dysphonia</condition>
  <arm_group>
    <arm_group_label>DBS On</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DBS Off</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBS ON</intervention_name>
    <description>The DBS system will be turned on and the patient will be left on their best setting for 3 months.</description>
    <arm_group_label>DBS On</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBS OFF</intervention_name>
    <description>The DBS system will be turned off, and will be left off for 3 months.</description>
    <arm_group_label>DBS Off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of spasmodic dysphonia&#xD;
&#xD;
          -  Patient is receiving Botox treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have muscle tension dysphonia or vocal tremor&#xD;
&#xD;
          -  Patients who have had laryngeal denervation surgery&#xD;
&#xD;
          -  Patients with mild symptoms&#xD;
&#xD;
          -  Patients who have any of the following MRI contraindications:&#xD;
&#xD;
               1. Patients with a cardiac pacemaker or defibrillator&#xD;
&#xD;
               2. Patients who have an insulin or infusion pump&#xD;
&#xD;
               3. Patients who have a cochlear, otological, or ear implant&#xD;
&#xD;
               4. Patients who have any implant held in place by a magnet&#xD;
&#xD;
               5. Patients who have any tissue expanders&#xD;
&#xD;
               6. Patients who have an implanted catheter, clamps, clips, valves, or other metal&#xD;
&#xD;
               7. Patients who have any tattoos or permanent makeup above shoulders&#xD;
&#xD;
               8. Patients who have any shrapnel or metal fragments&#xD;
&#xD;
               9. Patients who have had metal removed from their eye&#xD;
&#xD;
              10. Patients who have worked with metal&#xD;
&#xD;
              11. Patients who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher R Honey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah Polyhronopoulos, BSc</last_name>
    <phone>604-875-4111</phone>
    <email>leahpoly@mail.ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leslie and Gordon Diamond Health Care Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Christopher R Honey, MD, DPhil</last_name>
      <phone>604-875-5894</phone>
      <email>chris.honey@telus.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug;53(8):633-9.</citation>
    <PMID>2213039</PMID>
  </reference>
  <reference>
    <citation>White LJ, Klein AM, Hapner ER, Delgaudio JM, Hanfelt JJ, Jinnah HA, Johns MM 3rd. Coprevalence of tremor with spasmodic dysphonia: a case-control study. Laryngoscope. 2011 Aug;121(8):1752-5. doi: 10.1002/lary.21872.</citation>
    <PMID>21792965</PMID>
  </reference>
  <reference>
    <citation>Bielamowicz S, Stager SV, Badillo A, Godlewski A. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. J Voice. 2002 Mar;16(1):117-23.</citation>
    <PMID>12002878</PMID>
  </reference>
  <reference>
    <citation>Zwirner P, Murry T, Swenson M, Woodson GE. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope. 1992 Apr;102(4):400-6.</citation>
    <PMID>1556889</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Christopher Honey</investigator_full_name>
    <investigator_title>Professor of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Deep Brain Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysphonia</mesh_term>
    <mesh_term>Hoarseness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

